Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Lineage Cell Therapeutics

Lineage Cell Therapeutics (NYSE: LCTX) insider transactions

In the twelve months to 10 November 2026, executives and directors of Lineage Cell Therapeutics reported 0 open-market sales and 1 open-market purchase of 15,000 shares ($24,450), by 1 person, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 18 most recent transactions in Lineage Cell Therapeutics shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
12 March 2026Culley Brian MPresident and CEOOpen-market purchase+15,000$1.63255,516Form 4
11 February 2026Samuel George A. IIIGeneral Counsel and SecretaryOption exercise+6,075—33,565Form 4
11 February 2026Samuel George A. IIIGeneral Counsel and SecretaryShares withheld for tax−2,502$1.8031,063Form 4
11 February 2026Culley Brian MPresident and CEOOption exercise+31,250—253,385Form 4
11 February 2026Culley Brian MPresident and CEOShares withheld for tax−12,869$1.80240,516Form 4
19 December 2025Samuel George A. IIIGeneral Counsel and SecretaryGrant or award+1,735—27,555Form 4
19 December 2025Samuel George A. IIIGeneral Counsel and SecretaryShares withheld for tax−65$1.6827,490Form 4
19 December 2025Culley Brian MPresident and CEOGrant or award+8,925—222,469Form 4
19 December 2025Culley Brian MPresident and CEOShares withheld for tax−334$1.68222,135Form 4
11 February 2025Culley Brian MPresident and CEOOption exercise+31,249—226,091Form 4
11 February 2025Culley Brian MPresident and CEOShares withheld for tax−12,547$0.65213,544Form 4
11 February 2025Samuel George A. IIIGeneral CounselOption exercise+6,076—28,260Form 4
11 February 2025Samuel George A. IIIGeneral CounselShares withheld for tax−2,440$0.6525,820Form 4
27 January 2025Broadwood Capital Inc—Open-market purchase+7,894,737$0.7649,560,992Form 4
26 November 2024Samuel George A. IIIGeneral CounselOpen-market purchase+15,000$0.6022,184Form 4
26 November 2024Howe Jill AnnChief Financial OfficerOpen-market purchase+15,000$0.5925,500Form 4
22 November 2024Mulroy Michael H.DirectorOpen-market purchase+40,000$0.57298,555Form 4
21 November 2024Culley Brian MPresident and CEOOpen-market purchase+40,000$0.60194,842Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Lineage Cell Therapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.